Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Chronic kidney disease can be described as the gradual loss of kidney function. In this chronic condition, kidneys can be damaged and cannot filter blood the way they should filter ideally. Chronic kidney disease may be caused by diabetes, high blood pressure, and other disorders. If kidney disease gets worse, metabolic wastes can build to high levels in patient’s blood and make them feel sick. Chronic kidney disease complications include high blood pressure, anemia (low blood count), weak bones, poor nutritional health, and nerve damage. Chronic kidney disease increases the risk of developing heart and blood vessel diseases such as heart attack, stroke etc. These problems may happen slowly over a long period of time.
The global chronic kidney disease drugs market is estimated to be valued at US$ 12,328.2 million in 2020 and is expected to exhibit a CAGR of 4.0% over the forecast period (2020-2027).
Figure 1. Global Chronic Kidney Disease Drugs Market Share (%), By Region, 2020
Increasing prevalence of chronic kidney disease is expected to drive the market growth over the forecast period
The increasing prevalence of chronic kidney disease is expected to drive growth of the global chronic kidney disease drugs market. For instance, according to the Centers for Disease Control and Prevention (CDC), 15% of adults in the U.S., which is around 37 million people, were estimated to have chronic kidney disease in 2019.
Moreover, according to the data published in the Indian Journal of Public Health (IJPH), in 2018, around 130,000 patients received dialysis treatment in India, and the number increased by around 232 patients per million population in India from previous year
Furthermore, adoption of inorganic growth strategies by major companies operating in this market such as collaborations, agreements, partnerships, and acquisitions to strengthen their market share is further fuelling growth of the global chronic kidney disease drugs market. For instance, in January 2017, Amgen, Inc. entered into a six year sourcing and supply agreement with DaVita Inc., a healthcare company, which offers kidney dialysis services. Under this agreement, Amgen will supply Epogen and Aransep, major anemia drugs, to DaVita Inc.
Figure 2. Global Chronic Kidney Disease Drugs Market Share (%), by Drug Type, 2020
Increasing launches and approval of products are expected to drive the market growth over the forecast period
Key players operating in the market are focusing on novel product launches and approvals, in order to expand their product portfolio and strengthen their presence in the global market.
For instance, in August 2017, Amgen, Inc. received approval from the European Commission (EC) for expanded use of Mimpara (cinacalcet) for the treatment of secondary hyperparathyroidism (HPT) in children aged three years and older with end?stage renal disease (ESRD) on dialysis and where secondary HPT is not adequately controlled with standard of care therapy.
Furthermore, in February 2017, Amgen, Inc. received approval from the U.S. Food and Drug Administration (FDA) for its Parsabiv (etelcalcetide) indicated for the treatment of secondary hyperparathyroidism (sHPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.
Chronic Kidney Disease Drugs Market Report Coverage
||Market Size in 2020:
||US$ 12,328.2 Mn
|Historical Data for:
||2016 to 2019
||2020 to 2027
|Forecast Period 2020 to 2027 CAGR:
||2027 Value Projection:
||US$ 16,222.7 Mn
- North America: U.S. and Canada
- Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
- Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
- Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
- Middle East: GCC Countries, Israel, and Rest of Middle East
- Africa: South Africa, North Africa, and Central Africa
- By Drug Type: ACE Inhibitors, B-blockers, Calcium Channel Blockers, Loop Diuretics, Erythropoiesis-stimulating Agents (ESAs), Phosphate Binders, Others.
- By Route of Administration: Oral, Intravenous, Subcutaneous.
- By Patient Type: Dialysis, Others.
- By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.
Amgen, Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., AstraZeneca Plc, Hoffmann La Roche Ltd., Sanofi S.A., Kissei Pharmaceutical Co. Ltd., AbbVie Inc., Reata Pharmaceuticals, Inc., GlaxoSmithKline Plc, and Ardelyx, Inc.
- Increasing prevalence of chronic kidney disease
- Product approvals and launches for the treatment of chronic kidney disease
- Adoption of inorganic growth strategies by market players
|Restraints & Challenges:
- Lack of awareness about chronic kidney disease
Global Chronic Kidney Disease Drugs Market – Impact of Coronavirus (Covid-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it as a public health emergency. According to the Coronavirus Disease (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 49.7 million cases and 1.2 million deaths due to coronavirus disease (COVID-19) were reported up till November 08, 2020, across the globe. With dynamically surging cases of COVID-19, the risk for patients acquiring chronic kidney disease is also increasing. According to a study conducted in May 2020, by the researchers at Mount Sinai Health System, New York City, U.S., an epidemic of post-COVID-19 kidney disease might occur after the COVID-19. Moreover, according to the National Kidney Foundation, a study found that patients hospitalized during March 11 and April 26, 2020, due to COVID-19 were twice as likely to develop acute kidney injury (AKI) as compared to non-COVID patients, who developed AKI during the same time period in 2019.
The COVID-19 pandemic has drastically affected clinical trials. Many trials have paused enrollment and researchers are facing multiple challenges associated with setting up remote visits, and performing laboratory and other study assessments. According to a survey conducted by Medidata Solutions, Inc. (a U.S.-based technology company, which develops and markets software as a service for clinical trials), on April 23, 2020, 63% of survey respondents reported that they stopped recruiting new patients for ongoing clinical trials and 43% of the respondents have postponed their studies. However, market players and research institutes are focusing on initiating clinical trials associated with COVID-19, in order to understand the effects of chronic kidney disease treatment drugs on patients suffering with COVID-19.
Global Chronic Kidney Disease Drugs Market - Restraint
Lack of awareness about chronic kidney disease is the major factor that is expected to restrain growth of the chronic kidney disease drugs market. Despite the attempts by government to increase awareness about chronic kidney disease (CKD) through dissemination of clinical practice guidelines and recommendations for patients with CKD or its risk factors, community awareness events such as World Kidney Day, and free screening efforts for high-risk individuals such as Kidney Early Evaluation Program (KEEP), the awareness of CKD remains unacceptably low. For instance, in March 2018, a cross-sectional study for chronic kidney disease evaluation was published in BMC Public Health, according to which the people in Australia have very poor understanding of chronic kidney disease (CKD) and only half of the participants knew that medications can help to slow the worsening of CKD. Furthermore, only 23.4% of participants of total chronic kidney disease knew that herbal supplements are ineffective in treating CKD.
Major players operating in the global chronic kidney disease drugs market include Amgen, Inc., Teva Pharmaceutical Industries Ltd., Pfizer Inc., AstraZeneca Plc, Hoffmann La Roche Ltd., Sanofi S.A., Kissei Pharmaceutical Co. Ltd., AbbVie Inc., Reata Pharmaceuticals, Inc., GlaxoSmithKline Plc, and Ardelyx, Inc.